Patients For Affordable Drugs NOW

P4ADNow is a bipartisan patient advocacy organization fighting for lower drug prices. We mobilize patients in support of legislation to fix our broken system.

[Patients For Affordable Drugs NOW @P4ADNOW]

NEW VIDEO: We just released a new video explaining one of the most important — and least talked about — drivers of high drug prices: patent abuse. The ETHIC Act would close the loopholes drug companies exploit to block cheaper generics. Watch, share, and urge Congress to act: https://t.co/CRR9ojek4E

[Patients For Affordable Drugs NOW @P4ADNOW]

Launch price of drugs jumped 35% between 2022-2025, after the Fifth Circuit rejected PhRMA’s challenge this summer, the group filed an en banc petition, and Maryland Gov. backed legislation allowing the state’s PDAB to set upper payment limits based on prices negotiated by Medicare. Read more at our Week in Review: https://t.co/oyHctvJTO1

Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: https://t.co/rteVwsZcxi

[Patients For Affordable Drugs NOW @P4ADNOW]

Big Pharma's abuse of the patent system has made it harder for generics and biosimilars to come to market to lower drug prices for patients, but the bipartisan Eliminating Thickets to Improve Competition (ETHIC) Act could help change that.

The ETHIC Act addresses double patenting by allowing a generic manufacturer to challenge only one key patent in a patent family to invalidate duplicative patents. Helping to close a loophole that Big Pharma has relied on to block competition and keep prices artificially high.

Big Pharma’s army of lobbyists is working to stop common-sense reforms like the ETHIC Act. Make sure they don’t get their way -- send a letter to your representative urging them to support ETHIC today: https://t.co/H5Fnmceb1V

[Patients For Affordable Drugs NOW @P4ADNOW]

CEO Merith Basey sat down with Ken Rosato from @onnewjersey to discuss the drug pricing crisis in the United States. Merith shares the story behind P4AD, how we got started, our key priorities, and what we’re hoping to achieve.

Still have questions or want to get involved? We’d love to hear from you! Send us a DM. 💬

[Patients For Affordable Drugs NOW @P4ADNOW]

💔 Patients like Beck shouldn't have to ration their insulin due to cost, and yet, stories like hers are all too common.

Insulin is essential for people with diabetes, but many people with private insurance still face high out-of-pocket costs. The bipartisan INSULIN Act would cap monthly insulin costs at $35 for people with private insurance, helping make this lifesaving medication more affordable.

Patients and families deserve to be heard. Write to your members of Congress and urge them to pass the INSULIN Act: https://t.co/2RUIBU5B9a

[Patients For Affordable Drugs NOW @P4ADNOW]

Hispanic and Latino communities are disproportionately harmed by high drug prices, but make up just a fraction of the patient advocates fighting back against big drug companies. Get involved, stand with other patients, and lend your voice to help change policy! Share your story with P4AD: https://t.co/FXm356G48T

Las comunidades hispanas y latinas se ven afectadas de manera desproporcionada por los altos precios de los medicamentos, pero representan solo una pequeña parte de los pacientes defensores que luchan contra las grandes compañías farmacéuticas. ¡Involúcrate, únete a otros pacientes y alza tu voz para ayudar a cambiar las políticas! Comparte tu historia con P4AD: https://t.co/RjHDDMdddf

[Patients For Affordable Drugs NOW @P4ADNOW]

CBP announced that it is delaying a change in personal implementation requirements by 90 days, nearly 40% of FDA advisory meetings included patient representatives tied to Big Pharma-funded advocacy groups, and a new industry-backed bill would make it easier for certain biologic drugs to delay their eligibility for Medicare negotiation. Read more at our Week in Review: https://t.co/HsIGOPRraY

Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: https://t.co/rteVwsZcxi

[Patients For Affordable Drugs NOW @P4ADNOW]

What's one of the biggest drivers of high drug prices? 🤔

Big drug company patent abuse.

The P4AD-endorsed ETHIC Act would close a loophole drug companies exploit to block cheaper generics from coming to market and lowering costs for patients. Watch, share, and urge Congress to act: https://t.co/KnSOiLJ1mW

[Patients For Affordable Drugs NOW @P4ADNOW]

💔 Sa'Ra and her sister have been forced to share insulin because of the unaffordable price. This is unacceptable, yet stories like theirs are all too common. According to a 2024 report from T1International, nearly 37% of respondents reported rationing insulin due to cost.

The bipartisan INSULIN Act would establish a $35 monthly out-of-pocket cap for insulin for people with private insurance, making this lifesaving medication more affordable and reducing barriers to care.

Send a letter to your members of Congress today and urge them to pass the bipartisan INSULIN Act: https://t.co/2RUIBU5B9a

[Patients For Affordable Drugs NOW @P4ADNOW]

The Medication Affordability and Patent Integrity Act (S. 2658) would strengthen oversight of the patent system and close loopholes that delay competition.

When competition enters the market, prices go down significantly.

In fact, when there are six or more generic competitors on the market to compete with brand-name products, prices can fall by up to 95%.

That’s why P4AD supports this bill. Write a letter to your Senator today in support of The Medication Affordability and Patent Integrity Act: https://t.co/1yuDYEP5VT

[Patients For Affordable Drugs @P4AD_]

Big news! Our US v. Pharma: Fighting to Protect Medicare Negotiation campaign has been named a finalist for the Anthem Awards!

Medicare drug price negotiation is a historic step toward lowering prescription drug prices, but the policy can be complex and difficult to connect with audiences beyond Medicare beneficiaries. That’s why we partnered with digital creators to bring this issue to life through authentic storytelling and make it more accessible and relevant to younger and more diverse audiences.

Selected from more than 2,500 projects, we’re proud to see this work recognized alongside other campaigns driving social impact. Now, we need your help!

Vote for P4AD for the Anthem Community Voice Award and help us celebrate this work: https://t.co/Us8O7s8PXZ

Voting is open through October 29. Don’t forget to verify your email after voting to make sure your vote counts!

Thank you for helping us keep up the fight for lower prescription drug prices! #AnthemAwards @anthemawards

[Patients For Affordable Drugs NOW @P4ADNOW]

AstraZeneca revived one of its multiple lawsuits against Medicare negotiation, PhRMA filed a lawsuit challenging the Trump administration’s GLOBE model, and new KFF polling confirms that healthcare costs remain Americans’ top affordability concern. Read more at our Week in Review: https://t.co/UZVs81kUee

Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: https://t.co/rteVwsZcxi

[Patients For Affordable Drugs NOW @P4ADNOW]

P4AD patient advocate Jackie relies on the 2022 prescription drug law's $2,000 cap on out of pocket costs to afford the medication she needs to survive. To learn more about the 2022 prescription drug law and how it's helping patients save money at the pharmacy, visit https://t.co/IqGN4WE2mm

[Patients For Affordable Drugs NOW @P4ADNOW]

Use your voice to help change policy! Every story contributes to the larger picture of what real patients are facing and helps build a stronger, more powerful movement for change. Share your story with P4AD: https://t.co/z6gXxf5emJ

¡Usa tu voz para cambiar las políticas! Cada historia contribuye a construir una imagen más completa de lo que enfrentan los pacientes en la vida real y ayuda a construir un movimiento más fuerte y poderoso para impulsar cambio. Comparte tu historia con P4AD: https://t.co/RjHDDMdddf

[Patients For Affordable Drugs NOW @P4ADNOW]

Humira is a great example of how big drug companies abuse the patent system to extend monopolies, avoid competition, and keep prices high.

9 in 10 Americans are urging Congress to do more to lower the cost of prescription drugs in the U.S. It’s time for Congress to rein in Big Pharma’s unchecked greed and help the millions of patients that have to skip or ration their meds due to their high cost.

[Patients For Affordable Drugs NOW @P4ADNOW]

GLOBE’s projected Medicare savings fell from $11.9B to just $440M due to Pharma carveouts, 56 members of Congress are urging CMS to weaken Medicare Negotiation, patients respond to the new CBP rule that will make it harder to import lower-cost prescription drugs from abroad, and Eric Cantor named next President and CEO of PhRMA. Read more at our Week in Review: https://t.co/Rm2gd5LVDT

Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: https://t.co/rteVwsZcxi

[Patients For Affordable Drugs NOW @P4ADNOW]

When Big Pharma games the patent system, patients pay the price. But there are bipartisan bills in Congress that would bring lower cost competition to market faster by curbing Big Pharma's abuse of the patent system. Visit https://t.co/EAkF0gmPJh to learn more and get involved.

[Patients For Affordable Drugs NOW @P4ADNOW]

.@SenPeterWelch is right. When pharmaceutical companies abuse the patent system to extend their monopolies, they’re ripping off the American people.

One example of these greedy practices is AbbVie’s Humira. In 2016, before the expiration of the core patent for Humira, AbbVie obtained between 105 and 132 patents.

This patent thicket helped AbbVie delay competition for years, keeping lower-cost biosimilar versions of Humira off the market and forcing patients to pay more for the drug.

Drug companies can’t be allowed to manipulate the patent system to protect their high prices.

To learn more about how drug companies are manipulating the patent system visit: https://t.co/auW8vCuWj4

[Patients For Affordable Drugs NOW @P4ADNOW]

The ETHIC Act would help bring lower-cost competition to market sooner by limiting the number of patents drugmakers can assert to one patent per invention family during litigation. But Big Pharma's lobbyists are working every day to stop the bill from being passed.

Fight back against pharmaceutical greed! Urge Congress to act: https://t.co/CRR9ojek4E

[Patients For Affordable Drugs NOW @P4ADNOW]

El proyecto de Ley ETHIC reduciría el costo de los medicamentos recetados y frenaría el abuso del sistema de patentes por parte de las compañías farmacéuticas al abordar la práctica de patentamiento doble. Sin embargo, los cabilderos de la gran industria farmacéutica están trabajando arduamente para detenerlo.

¡Hay que pelear en contra de la codicia de la gran industria farmacéutica! Envía una carta a tu representante y pídele que ponga a los pacientes primero apoyando el proyecto de Ley ETHIC hoy mismo: https://t.co/xM2e7lIudg

----

The ETHIC Act would lower prescription costs and reduce drug company patent abuse by addressing double patenting but Big Pharma's lobbyists are hard at work against it.

Fight back against Big Pharma greed! Send a letter to your representative urging them to put patients first by supporting the ETHIC Act today: https://t.co/CRR9ojek4E

[Patients For Affordable Drugs NOW @P4ADNOW]

Newly released, heavily redacted FOIAd MFN agreements reveal little about the actual deals, BRG executives spoke candidly about the financial calculations behind investment in new treatments, and a new Customs and Border Protection ruling could make it more difficult to purchase medications overseas. Read more at our Week in Review: https://t.co/Cv7cvpEn5h

Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: https://t.co/rteVwsZcxi